<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03181191</url>
  </required_header>
  <id_info>
    <org_study_id>UHG-CFD-PX-BIOPSY</org_study_id>
    <nct_id>NCT03181191</nct_id>
  </id_info>
  <brief_title>The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion</brief_title>
  <official_title>The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mille Baekdal Nielsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Delineation of the anatomical location, cellular origin and molecular basis of gut-derived
      glucagon secretion
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: to delineate the anatomical origin, the molecular structure and precursors, the
      regulation and the (patho-) physiological implications of gut-derived glucagon.

      Eight totally pancreatectomised patients, eight type 2 diabetes patients and eight healthy
      controls (age 18-80, BMI &lt;30) with normal kidney and liver parameters and hgb&gt; 6.5 - will be
      included. The participants will each undergo one screening day and one study day including a
      gastroduodenoscopy. Multiple biopsies will be taken at several predefined locations in the
      upper gastrointestinal tract. These biopsies will be analysed with different techniques
      including immunohistochemical staining, quantitative polymerase chain reaction (qPCR-)
      analyses and more to search for glucagon. After the last biopsy has been collected, 50 g of
      glucose dissolved in 100 ml water is infused through the enteroscope into the most proximal
      part of the small intestine. Hereafter blood samples for glucagon and gut hormone analyses
      will be collected 15, 30 and 45 min after the glucose infusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gut-derived glucagon</measure>
    <time_frame>1 year</time_frame>
    <description>The primary objective is to investigate mucosal biopsies from specific regions of the upper gastrointestinal tract</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral glucose tolerance test</measure>
    <time_frame>45 minutes</time_frame>
    <description>Glucose metabolism - hormones, insulin, glucagon, glp-1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Totally pancreatectomised patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral glucose tolerance test and biopsies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetes patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral glucose tolerance test and biopsies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral glucose tolerance test and biopsies</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral glucose tolerance test</intervention_name>
    <description>Oral glucose tolerance test and biopsies</description>
    <arm_group_label>Totally pancreatectomised patients</arm_group_label>
    <arm_group_label>Type 2 diabetes patients</arm_group_label>
    <arm_group_label>Healthy control subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  normal kidney function, normal liver function, normal hemoglobin levels

        Exclusion Criteria:

          -  diabetes type 1, first degree relatives with type 2 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip Knop, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Gentofte, Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mille Baekdal, MD</last_name>
    <phone>+45 26700782</phone>
    <email>mille.baekdal.nielsen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Filip Knop, MD, PhD</last_name>
    <email>filipknop@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Diabetes Research</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mille Baekdal, MD</last_name>
      <phone>+45 26700782</phone>
      <email>mille.baekdal.nielsen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Filip Knop, MD, PhD</last_name>
      <email>filipknop@dadlnet.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Mille Baekdal Nielsen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

